Artikelen door HollandBIO

New at Pivot Park: GlycoMScan

GlycoMScan has opened their company’s doors in the van Leeuwenhoek building’s basement. GlycoMScan offers services in mass spectrometry, from screening of small molecules to absolute quantification in complex biological matrices. “As the name suggests, I am specialized in analyses of glycosylation and the building blocks thereof, the nucleotide sugars and phosphorylated sugars from intracellular metabolism,” […]

GM golden rice gets approval from food regulators in the US

GOLDEN rice, which has been genetically modified to prevent blindness in undernourished children, was judged safe to eat last week by the US Food and Drug Administration. The rice contains extra genes that make a precursor to vitamin A, which is vital for preventing childhood blindness. A single helping can supply half the recommended daily […]

Treeway prepares phase 3 study for TW001 to treat ALS

Phase 1 study suggests that novel oral formulation improves bioavailability while remaining well tolerated. Treeway, a biotech company developing therapies against amyotrophic lateral sclerosis (ALS), announced the completion of its Phase I trial of lead program TW001, an oral formulation of edaravone. The study compared the bioavailability of TW001 in its novel market formulation to […]

, ,

Invest-NL als vliegwiel voor innovatie

Op donderdag 31 mei organiseert de vaste Kamercommissie EZK een rondetafelgesprek over de nieuwe investeringsinstelling Invest-NL. Hierbij komen verschillende stakeholders aan het woord. HollandBIO’s Annemiek Verkamman zal namens de biotech sector pleiten voor een ijzersterk innovatieklimaat met een uitgekiende financieringsmix voor life sciences bedrijven. Op deze manier hebben bedrijven in alle fases van ontwikkeling toegang […]

,

AVG-programma

Vanaf 25 mei 2018 moeten alle bedrijven en organisaties voldoen aan de nieuwe privacy wetgeving: de Algemene Verordening Gegevensbescherming (AVG). Bestuurders zijn persoonlijk aansprakelijk. Heb je als organisatie je zaken niet op orde? Dan kan de Autoriteit Persoonsgegevens een forse boete opleggen. De stichting AVG verenigingen heeft voor het MKB een programma ontwikkeld waarmee je […]

EuropaBIO: SPC waiver risks downgrading the EU as a hub for health innovation

As an association that has manufacturers of both originator and biosimilar medicines as members, EuropaBio strongly doubts that the promises of today’s Commission proposal outweigh the risks of losing investment in new medicines. “Today’s proposal can only weaken the attractiveness of the EU as a hub for biopharmaceutical innovation. The approach of taking incentives away […]

,

Hartwig Medical Foundation and ttopstart announce collaboration

Hartwig Medical Foundation and ttopstart are pleased to announce collaboration to accelerate the implementation of clinical decision support systems for personalised cancer treatment in the Netherlands. Hartwig Medical Foundation is developing innovative clinical decision support systems to enable personalised cancer treatment in the Netherlands. As a part of this, Hartwig Medical Foundation provides access to a unique […]

Merus’ MCLA-158 Phase I clinical trial has started

Merus, a clinical-stage immuno-oncology company developing innovative bispecific antibody therapeutic, announced that the first patient has been dosed in a Phase 1, first-in human clinical trial of MCLA-158 in patients with solid tumors with an initial focus on metastatic colorectal cancer. The trial will be conducted in Europe, where several Clinical Trial Applications (CTAs) have […]

Pink pineapples and healthy fries

From health benefits to increased flavour and longer shelf-life, discover the new generation of GM foods designed with the consumer in mind. Non-browning apples Some people dislike eating fruit with flesh that has become discoloured. This never happens to Arctic apples. They went on sale in the US in November 2017. Potatoes that don’t bruise […]

,

Lava Therapeutics Raises EUR 16 Million

Gilde Healthcare and Versant Ventures have driven Lava Therapeutics to a €16 million ($18.8 million) financing. The round equips Lava to advance bispecific engagers of gamma-delta (γδ) T cells, a small subgroup of lymphocytes involved in natural and induced immunity to cancer. Like other bispecific T-cell engagers, Lava’s drugs are designed to activate the lymphocytes […]